The long-acting anti-C5 ravulizumab results in C3 binding to PNH red cells similar to its parental molecule eculizumab. Sica M, Barone F, Nannelli C, Ricci P, et al. Br J Haematol 2023;201:e1-e4.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Sica M, Barone F, Nannelli C, Ricci P, et al. The long-acting anti-C5 ravulizumab results in C3 binding to PNH red cells similar to its parental molecule eculizumab. Br J Haematol 2023;201:e1-e4.
PMID: 36660816